Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novo Nordisk A/S
The decision to discontinue the development of AERx® is not due to any safety concerns. An analysis concluded that fast-acting inhaled insulin in the form it is known today, is unlikely to offer significant clinical or convenience benefits over injections of modern insulin with pen devices.
Age
30–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Chronic Obstructive Pulmonary Disease
Type 1 or type 2 diabetes
HbA1c lower or equal to 11.0 %
Body Mass Index (BMI) lower or equal to 40.0 kg/m2
You may not be if
Recurrent severe hypoglycaemia
Current smoking or smoking within the last 6 months
Other pulmonary disease including asthma
Proliferative retinopathy or maculopathy requiring acute treatment
